Broad-spectrum cancer drug is goal of multinational project

January 15, 2014

A multinational set of seven teams is banding together to develop a drug that may potentially fight many different cancers through an antibody that would work within the body's metabolic system.

Tyler Curiel, M.D., M.P.H., a cancer immunologist at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, and professor in the School of Medicine there, is part of the European Union's TumAdoR project. The project grants $8 million among the researchers over four years to develop an antibody that will block a specific cancer metabolic pathway and reduce its ability to suppress the immune system. The objective is to have the antibody developed and ready for clinical trials at the end of the grant period.

"It can take decades to be in a clinical trial with a new concept and we're trying to do it in four years," Dr. Curiel said. "I think we've got a pretty good shot."

Dr. Curiel is the leader for TumAdoR Project 6, funded at $800,000. His team's mission is to develop mice with human immune systems and other models and additional tests to be sure that the developed antibody can block the metabolic pathway, and to assess what the immune consequences will be in humans.

The TumAdoR project weaves together the skills of seven different teams from Germany, Switzerland, France, Finland and the UT Health Science Center to attack the problem from multiple perspectives such as immunology, drug development, and clinical trial design and management.

Its target is CD73, an enzyme that is overexpressed in many different kinds of cancer. CD73 helps produce excess amounts of adenosine, which is needed to produce energy in cells, but also can suppress the immune system and allow the tumor cells to reproduce.

Adenosine is not normally immune-suppressive, "but it is when you generate lots of it, as tumors do. Tumors do everything in a crazy way," Dr. Curiel said.

Antibody therapy is already a proven success -- one example is Herceptin, an antibody drug used to treat breast cancer -- but the promising thing about this project is that the drug may well work against several types of cancer.
-end-
Bin Zhang, M.D., Ph.D., a former CTRC researcher who developed critical CD73 data, now at Northwestern University, remains a part of the Curiel team collaborating on Project 6. Christophe Caux, PhD, at the Léon Bérard Cancer Center in Lyon, France is principal investigator.

The TumAdoR project receives funding from the European Union's 7th Research Framework Programme (FP7).

For current news from the UT Health Science Center, please visit our news release website or follow us on Twitter @uthscsa.

The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the elite academic cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of only four in Texas. A leader in developing new drugs to treat cancer, the CTRC Institute for Drug Development (IDD) conducts one of the largest oncology Phase I clinical drug programs in the world, and participates in development of cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit http://www.ctrc.net.

University of Texas Health Science Center at San Antonio

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.